Repurposing DPP-4 Inhibitors for Colorectal Cancer : A Retrospective and Single Center Study
BACKGROUND: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the association between DPP4-inhibitor treatment and the prognosis of CRC patients.
METHODS: Clinical data of CRC patients with diabetes and the prescription of DPP4-inhibitors who had undergone curative surgery in our hospital between January 2006 and December 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared to those treated with metformin.
RESULTS: The DPP4-inhibitor patient group showed a significantly better 5-year disease-free survival (median DFS = 1733 days, 95% CI = 1596 to 1870 days) when compared to the metformin group (p = 0.030, median DFS = 1382 days, 95% CI = 1246 to 1518 days). 33 out of the 92 patients in the metformin group showed recurrence whereas only 3 of the 26 patients in the DPP4-inhibitor group showed recurrence (p = 0.033). Cox regression analysis demonstrated that DPP4-inhibitor application is a favorable factor associated with a lower risk of recurrence (Hazard ratio = 0.200, p = 0.035). Furthermore, our results suggested that the immune cell profile of CRC patients is a potential biomarker for response to DPP4-inhibitor treatment.
CONCLUSION: This study demonstrated the association of DPP4-inhibitor treatment with a better prognosis of CRC patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Cancers - 13(2021), 14 vom: 17. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ng, Lui [VerfasserIn] |
---|
Links: |
---|
Themen: |
CD26 |
---|
Anmerkungen: |
Date Revised 29.07.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/cancers13143588 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM328436658 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM328436658 | ||
003 | DE-627 | ||
005 | 20231225202928.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/cancers13143588 |2 doi | |
028 | 5 | 2 | |a pubmed24n1094.xml |
035 | |a (DE-627)NLM328436658 | ||
035 | |a (NLM)34298800 | ||
035 | |a (PII)3588 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ng, Lui |e verfasserin |4 aut | |
245 | 1 | 0 | |a Repurposing DPP-4 Inhibitors for Colorectal Cancer |b A Retrospective and Single Center Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 29.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a BACKGROUND: There have been studies reporting the crucial roles of Dipeptidyl-peptidase 4 (DPP4) in colorectal cancer (CRC) initiation and progression, whereas DPP4-inhibitors are safe Food and Drug Association (FDA)-approved drugs for treating diabetes. This study aims to investigate the association between DPP4-inhibitor treatment and the prognosis of CRC patients | ||
520 | |a METHODS: Clinical data of CRC patients with diabetes and the prescription of DPP4-inhibitors who had undergone curative surgery in our hospital between January 2006 and December 2015 were retrieved. Their survival data and immune cell population in circulatory blood were compared to those treated with metformin | ||
520 | |a RESULTS: The DPP4-inhibitor patient group showed a significantly better 5-year disease-free survival (median DFS = 1733 days, 95% CI = 1596 to 1870 days) when compared to the metformin group (p = 0.030, median DFS = 1382 days, 95% CI = 1246 to 1518 days). 33 out of the 92 patients in the metformin group showed recurrence whereas only 3 of the 26 patients in the DPP4-inhibitor group showed recurrence (p = 0.033). Cox regression analysis demonstrated that DPP4-inhibitor application is a favorable factor associated with a lower risk of recurrence (Hazard ratio = 0.200, p = 0.035). Furthermore, our results suggested that the immune cell profile of CRC patients is a potential biomarker for response to DPP4-inhibitor treatment | ||
520 | |a CONCLUSION: This study demonstrated the association of DPP4-inhibitor treatment with a better prognosis of CRC patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a CD26 | |
650 | 4 | |a DPP4 | |
650 | 4 | |a DPP4-inhibitor | |
650 | 4 | |a colorectal cancer | |
650 | 4 | |a drug repurposing | |
650 | 4 | |a gliptin | |
650 | 4 | |a immune cell | |
700 | 1 | |a Foo, Dominic Chi-Chung |e verfasserin |4 aut | |
700 | 1 | |a Wong, Carlos King-Ho |e verfasserin |4 aut | |
700 | 1 | |a Man, Abraham Tak-Ka |e verfasserin |4 aut | |
700 | 1 | |a Lo, Oswens Siu-Hung |e verfasserin |4 aut | |
700 | 1 | |a Law, Wai-Lun |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 14 vom: 17. Juli |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2021 |g number:14 |g day:17 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13143588 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2021 |e 14 |b 17 |c 07 |